IgA Nephropathy and Berger Disease
Vera Therapeutics Inc. focuses on clinical research in IgA nephropathy, also referred to as Berger disease, with studies centered on kidney inflammation and proteinuria in both adults and pediatric populations.
- IgA nephropathy
- Berger disease
- Proteinuria
The sponsor’s trial portfolio includes work in patients with active renal disease and ongoing interest in clinical outcomes relevant to glomerular injury.
Multiple Autoimmune Glomerular Diseases
Research activity also extends to multiple autoimmune glomerular diseases, reflecting interest in immune-mediated kidney disorders that affect the renal and urinary system.
- Autoimmune glomerular disease
- Renal and urinary disorders
- Kidney inflammation
These studies address disease mechanisms linked to glomerulonephritis and related renal conditions requiring targeted therapeutic development.
Atacicept in Renal Immunology
The sponsor’s clinical program is built around atacicept, with trials examining its role in immune-mediated kidney disease and its effects on markers associated with IgA nephropathy.
- Atacicept
- Immune-mediated kidney disease
- Gd-IgA1
Key areas of interest include renal biomarker response and the management of chronic glomerular disease.
Pediatric Nephrology
Vera Therapeutics Inc. also supports research in pediatric nephrology, with attention to children affected by IgA nephropathy and the clinical characterization of treatment response in younger patients.
- Pediatric cohorts
- Childhood IgA nephropathy
- Renal safety and tolerability
This area reflects therapeutic interest in kidney disease across age groups, including long-term management of chronic renal disorders.
